Drug Trial Radar · NCT04684628
68Ga-PSMA PET/CT in Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
500
Planned (sponsor's estimate)
Start
Dec 9, 2020
Primary completion
Jan 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- University of SaskatchewanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, multi-arm, open-label, phase III trial in up to 500 patients with biopsy-proven prostate cancer. Participants will receive regular standard of clinical care. The only study-specific procedures will the administration of 68Ga-PSMA-11 followed by a PET/CT (positron emission tomography/computed tomography) scan. Participants will be followed for two hours after the infusion for identification of any immediate adverse events (AE), and will be contacted by telephone after 7 to 14 days to enquire about any delayed AEs. PET/CT images, CT-alone images and bone scans will be read by separate readers who will not be blinded to all other clinical and imaging information. The standard of truth will be a consensus of the readers based on all available clinical, imaging, and histopathological information available for up to 6 months after the PET/CT scan.
Conditions
- Prostate Cancer
Interventions
68Ga-PSMA PET/CTDrug
Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity of 68Ga-PSMA-11 PET/CT compared to that of CT alone and bone scan in two different cohorts of prostrate cancer patients.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.